Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR35 | Q9HC97 | 12/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | ATM | Q13315 | 1/20 | 0.44 |
| ▸ | HTR1B | P28222 | 1/20 | 0.43 |
| ▸ | CYP1B1 | Q16678 | 2/20 | 0.41 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CDK2 | P24941 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL4985854 | 0.99 | GPR35 (0.49) | GPR35ALDH1A1ATMHTR1BCYP1B1 | |
| SCHEMBL4996207 | 0.86 | ATM (0.45) | GPR35ALDH1A1ATMHTR1BCDK2 | |
| SCHEMBL4990839 | 0.86 | ATM (0.57) | GPR35ATMHTR1BCDK2 | |
| Hydrochloric Acid SCHEMBL4985151 | 0.85 | ATM (0.56) | GPR35ATMHTR1BCDK2 | |
| SCHEMBL4988326 | 0.85 | HTR1B (0.57) | GPR35ALDH1A1ATMHTR1BCDK2 | |
| Hydrochloric Acid SCHEMBL4988384 | 0.84 | HTR1B (0.56) | GPR35ALDH1A1ATMHTR1BCDK2 | |
| SCHEMBL4985616 | 0.84 | MAOB (0.54) | GPR35ALDH1A1ATMHTR1BCYP1B1 | |
| SCHEMBL4985501 | 0.83 | GPR35 (0.52) | GPR35ALDH1A1ATMHTR1B | |
| SCHEMBL4994772 | 0.82 | GPR35 (0.52) | GPR35ATMHTR1BCYP1B1CYP1A1 | |
| Hydrochloric Acid SCHEMBL4982799 | 0.82 | GPR35 (0.51) | GPR35ALDH1A1ATMHTR1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050182050-A1 | Therapeutic heterocyclic compounds | ASTRAZENECA AB (SE) | 2005-08-18 | — | — | US | claimed |
| US-6812225-B2 | PYSCHOLOGICAL DISORDERS; ANTIDEPRESSANTS | ASTRAZENECA AB (SE) | 2004-11-02 | — | — | US | claimed |
| US-20030013708-A1 | Therapeutic heterocyclic compounds | ASTRAZENECA AB (SE) | 2003-01-16 | — | — | US | claimed |
| CN-1821236-B | Therapeutic heterocyclic compounds | ASTRAZENECA AB | 2010-06-23 | — | — | CN | disclosed |
| CN-100509794-C | Therapeutic heterocyclic compounds | ASTRAZENECA AB (SE) | 2009-07-08 | — | — | CN | disclosed |
| CN-100460402-C | Therapeutic benzopyranone compounds used as intermediates. | ASTRAZENECA AB (SE) | 2009-02-11 | — | — | CN | disclosed |
| CN-100384833-C | Therapeutic chroman compounds | ASTRAZENECA AB (SE) | 2008-04-30 | — | — | CN | disclosed |
| US-20080076759-A1 | Therapeutic Heterocyclic Compounds 507 | ASTRAZENECA AB (SE) | 2008-03-27 | — | — | US | disclosed |
| US-20080076759-A1 | Therapeutic Heterocyclic Compounds 507 | ASTRAZENECA AB (SE) | 2008-03-27 | — | — | US | disclosed |
| US-20080076759-A1 | Therapeutic Heterocyclic Compounds 507 | ASTRAZENECA AB (SE) | 2008-03-27 | — | — | US | disclosed |
| US-7285662-B2 | Therapeutic heterocyclic compounds | ASTRAZENECA AB (SE) | 2007-10-23 | — | — | US | disclosed |
| WO-2003037872-A1 | THERAPEUTIC QUINOLINE COMPOUNDS WITH 5-HT-ANTAGONISTIC PROPERTIES | ASTRAZENECA AB (SE) | 2003-05-08 | — | — | WO | disclosed |
| WO-2003037871-A1 | THERAPEUTIC QUINOLONE COMPOUNDS WITH 5-HT-ANTAGONISTIC PROPERTIES | ASTRAZENECA AB (SE) | 2003-05-08 | — | — | WO | disclosed |
| US-20030045668-A1 | Method for thickening aqueous systems using hydrophilic polyurethanes | FISCHER HERBERT (DE) | 2003-03-06 | — | — | US | disclosed |
| US-20030032759-A1 | A METHOD FOR FORMING AN ADHESIVE LAYER USING HYDROPHILIC POLYURETHANES RELATED APPLICATIONS | FISCHER HERBERT (DE) | 2003-02-13 | — | — | US | disclosed |
| US-20030013708-A1 | Therapeutic heterocyclic compounds | ASTRAZENECA AB (SE) | 2003-01-16 | — | — | US | disclosed |
| WO-2002055013-A2 | THERAPEUTIC CHROMONE COMPOUNDS | ASTRAZENECA AB (SE) | 2002-07-18 | — | — | WO | disclosed |
| WO-2002055012-A2 | THERAPEUTIC HETEROCYCLIC COMPOUNDS | ASTRAZENECA AB (SE) | 2002-07-18 | — | — | WO | disclosed |
| WO-2002055014-A2 | THERAPEUTIC CHROMAN COMPOUNDS | ASTRAZENECA AB (SE) | 2002-07-18 | — | — | WO | disclosed |
| US-6399735-B1 | POLYETHERURETHANE COPOLYMER; CARPET ADHESIVE | HENKEL KOMMANDITGESELLSCHAFT AUF AKTIEN (DE) | 2002-06-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080076759-A1 | Therapeutic Heterocyclic Compounds 507 | HTR1A, HTR1B, HTR1D | GPR35 113/4885ALDH1A1 592/4885ATM 613/4885 |
| US-20050182050-A1 | Therapeutic heterocyclic compounds | HTR1B, HTR1D, HTR1A | GPR35 214/4885ALDH1A1 517/4885ATM 814/4885 |
| US-20030013708-A1 | Therapeutic heterocyclic compounds | HTR1A, HTR1D, HTR1B | GPR35 251/4885ALDH1A1 399/4885ATM 934/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.